M/S Genomic Valley
Biotech Limited, a Limited company as per Indian Company Law, has
been incorporated to delve deep into the business and research
possibilities of the most enigmatic field - Biotechnology. With the
talented and professional Chairman and Managing Director, Mr. Yogesh
Agrawal at the helm of activities with his futuristic dream, the
company is all set to march forward.
The company is
presently having a Core Team of ten scientists and professionals of
Indian Origin. As per the outcome of the recent meeting of the core
team, M/S Genomic Valley Biotech Limited, is aiming to be the only
Biotech Company in India to have wide perspective in the field
touching all the aspects through Creation, Training, and Marketing
in this most enigmatic arena of Biotechnology.
GVBL is having an
unique combination of activities to contribute towards its Revenue
Model. The activities are as follows :
- Creation of Brain
Research & Development Facility
Collaboration for R&D Projects
The company is in the
process of crating a "Brain Pool" by inducting the talented
scientists, and professionals in the Biotechnology field, thus
creating a Talented & Capable Team, to cater the national &
international Research Needs through Exchange Program. The "Brain
Pool" will conduct research for third parties internationally thus
generating revenue for the company.
The "Brain Pool" will
conduct internal research for inventing Biotechnology formulations
which will in turn generate revenue when commercialized.
Having support from all
corners, the company is all set to start its own institute by the
name and style "Genomic Valley Biotech Institute" which will conduct
training for the upcoming talents in the biotechnology arena
commercially, thus generating revenue for the company.
The trained students
will be provided placements internationally through our commercially
operating Placement Cell, which will also cater for outside students
professionally. This will add to the revenue of the company.
The company is coming
up with its Production Unit to commercially produce some of it's
Biotech Foermulae, and will keep on doing so as and when some
applied research will be conducted with success. This will be a
separate revenue generation unit for the company.
Presently, the company
is in the process of discussing the possibility to have a common
platform to act upon with some premier Biotech Institutes and
Biotech Companies internationally. Once an understanding is reached
we will be having a true International Platform to work and transact